Highlights Exact Sciences Corporation

Stocks

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-20 pm EDT			5-day change	1st Jan Change
104.91 ^USD	+0.95%		-.--%	+3.30%

Mar. 24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index	CI
Mar. 24	Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index	CI

Highlights

Mar. 23	Exact Sciences Corporation Announces Resignations of Board of Directors and Committees, Effective March 23, 2026	CI
Mar. 23	Abbott Laboratories Closes Acquisition of Exact Sciences	MT
Mar. 13	Walgreens Launches Colorectal Cancer Screening Program With Cologuard Test	CI
Feb. 23	Abbott Labs Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition	MT
Feb. 23	Abbott Laboratories Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition, Bloomberg Reports	MT
Feb. 20	Exact Sciences stockholders approve acquisition by Abbott	RE
Feb. 20	Exact Sciences Shareholders Approve Acquisition by Abbott Laboratories	MT
Feb. 13	Exact Sciences Q4 Loss Narrows, Revenue Rises	MT
Feb. 13	Earnings Flash (EXAS) Exact Sciences Corp. Reports Q4 Revenue $878.4M, vs. FactSet Est of $860.9M	MT
Feb. 13	Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 03	Exact Sciences Corp. Announces A Significant Milestone for Its Oncotype DX Breast Recurrence Score Test	CI
Jan. 30	German cartel office approved planned acquisition of Exact Sciences by Abbott	RE
Dec. 30	Alert from law firm on Exact Sciences-Abbott deal withdrawn	RE
Dec. 11	Exact Sciences Corp. Announces the First Clinical Study Results from Its Oncodetect Molecular Resistant Disease Test in Early Triple-Negative Breast Cancer	CI
Nov. 24	Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence At 2025 San Antonio Breast Cancer Symposium	CI
Nov. 20	Top Midday Gainers	MT
Nov. 20	Abbott Laboratories Eyes Entry Into Cancer Diagnostics Space With $21 Billion Exact Sciences Buyout	MT
Nov. 20	Abbott Laboratories to Acquire Exact Sciences for $21 Billion	MT
Nov. 20	Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments	RE
Nov. 20	Abbott - deal expected to be dilutive to adjusted earnings per share through 2027 - SEC filing	RE
Nov. 20	Correction to Abbott to Acquire Exact Sciences for $21 Billion Article	DJ
Nov. 20	Abbott to Acquire Exact Sciences for $21 Billion -- Update	DJ
Nov. 20	Abbott Laboratories to Acquire Exact Sciences for $21 Billion	MT
Nov. 20	Abbott Laboratories Agrees to Acquire Exact Sciences for $105 a Share	MT
Nov. 20	Abbott Laboratories to Acquire Exact Sciences for $21 Billion	MT